Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2014

Supporting Information

Fe-Catalyzed Oxidative C-H/N-H Coupling between Aldehydes

and Simple Amides

Jing Wang,^a Chao Liu,^a Jiwen Yuan,^a Aiwen Lei*^{a,b}

^a College of Chemistry and Molecular Sciences Wuhan University, Wuhan 430072, P. R. China.

^b National Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022,

Jiangxi, P. R. China *E-mail: <u>aiwenlei@whu.edu.cn</u>*

Copies of product ¹ H NMR and ¹³ C NMRS	513
---------------------------------------------------------------	-----

General information

All reactions were isolated from oxygen by a nitrogen atmosphere. All glassware was oven dried at 110 $^{\circ}$ C for hours and cooled down under vacuum. DCE was purified by distillation with CaH₂. Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. Thin layer chromatography (TLC) employed glass 0.25 mm silica gel plates. Flash chromatography columns were packed with 200-300 mesh silica gel in petroleum (bp.60-90 °C). Gas chromatographic analyses were preformed on Varian GC 2000 gas chromatography instrument with a FID detector and dibenzo[b,d]furan was added as internal standard. GC-MS spectra were recorded on a Varian GC-MS 3900-2100T. ¹H and ¹³C NMR data were recorded with Varian Mercury (400 MHz) spectrometers with tetramethylsilane as an internal standard. All chemical shifts (δ) are reported in ppm and coupling constants (*J*) in Hz. All chemical shifts are reported relative to tetramethylsilane and *d*-solvent peaks (77.00 ppm, chloroform), respectively.

General procedure for the oxidative coupling of amides with aldehydes

Amide (0.5 mmol) was added to a Schlenk tube equipped with a magnetic stir bar. Then, FeBr₂ (5.4 mg, 0.025 mmol) was added to the Schlenk tube in an argon-filled glove box. DCE (2.0 mL) was then injected into the tube by syringe. After stirring for 5 min, aldehyde (1.50 mmol) and TBHP (128.7 mg, 1.0 mmol, a 70% aqueous solution) were consecutively injected into the reaction tube. The reaction was then heated to 60 °C and stirred for 16 h. Upon completion, the reaction was quenched with water and extracted with ethyl ether (3 × 10 mL). The organic layers were then combined. The pure product was obtained by flash column chromatography on silica gel (petroleum/ethyl acetate= 10:1).

Procedure for eq.3

1a (74.6 mg, 0.5 mmol) was added to a Schlenk tube equipped with a magnetic stir bar. Then, FeBr₂ (5.4 mg, 0.025 mmol) was added to the Schlenk tube in an argon-filled glove box. DCE (2.0 mL) was then injected into the tube by syringe. After stirring for 5 min, **2a** (159.2 mg, 1.5 mmol) and TBHP (128.7 mg, 1.0 mmol, a 70% aqueous solution) were consecutively injected into the reaction tube. After stirring for 5 min, TEMPO (156.1 mg, 1.0 mmol) was added to the reaction tube in N₂ atmosphere. The reaction was then heated to 60 °C and stirred for 16 h. Upon completion, the reaction was quenched with water and extracted with ethyl ether (3 × 10 mL). The organic layers were then combined. The pure product was obtained by flash column chromatography on silica gel (petroleum/ethyl acetate= 200:1). The yield of the isolated product was 78% based on TEMPO.



N-Acetyl-N-benzylbenzamide (3aa). Compound 3aa was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 75%. ¹H NMR (400 MHz, CDCl₃) δ = 7.57 – 7.54 (m, 3H), 7.45 – 7.42 (m, 2H), 7.28 – 7.24 (m, 5H), 5.00 (s, 2H), 2.16 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 174.3, 173.2, 137.2, 135.7, 132.4, 128.7, 128.5, 128.3, 127.7, 127.4, 49.2, 26.4 ppm. HRMS (ESI) calcd for C₁₆H₁₅NO₂ [M+H]⁺: 254.1181; found: 254.1172.



N-Acetyl-N-benzyl-4-methylbenzamide (3ab). Compound 3ab was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-methylbenzaldehyde (180.0 mg, 1.5 mmol). Isolated yield = 64%. ¹H NMR (400 MHz, CDCl₃) δ = 7.47 (d, *J* = 8.1, 2H), 7.31 – 7.18 (m, 6H), 5.00 (s, 2H), 2.39 (s, 3H), 2.12 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 174.3, 173.1, 143.4, 137.3, 132.8, 129.4, 128.6, 128.4, 127.8, 127.3, 49.3, 26.3, 21.6 ppm. HRMS (APCI) calcd for C₁₇H₁₇NO₂ [M]⁺: 267.1259 found: 267.1259.



N-Acetyl-N-benzyl-3-methylbenzamide (3ac). Compound 3ac was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 3-methylbenzaldehyde (180.0 mg, 1.5 mmol). Isolated yield = 73%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36 – 7.22 (m, 9H), 5.00 (s, 2H), 2.35 (s, 3H), 2.12 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 174.6, 173.3, 138.8, 137.4, 135.7, 133.3, 129.0, 128.6, 128.5, 127.8, 127.4, 125.5, 49.3, 26.4, 21.3 ppm. HRMS (APCI) calcd for C₁₇H₁₇NO₂ [M]⁺:

267.1262; found: 267.1264.



N-Acetyl-N-benzyl-4-bromobenzamide (3ad). Compound 3ad was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-bromobenzaldehyde (277.5 mg, 1.5 mmol). Isolated yield = 80%. ¹H NMR (400 MHz, CDCl₃) δ = 7.55 (d, *J*=8.5, 2H), 7.41 (d, *J*=8.4, 2H), 7.31 – 7.17 (m, 5H), 4.98 (s, 2H), 2.19 (s, 3H). ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.3, 173.0, 136.9, 134.5, 132.0, 129.7, 128.6, 127.5, 127.2, 49.2, 26.2 ppm. HRMS (APCI) calcd for C₁₆H₁₄ BrNO₂ [M]⁺: 331.0211; found: 331.0213.



N-Acetyl-N-benzyl-2-bromobenzamide (3ae). Compound 3ae was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 2-bromobenzaldehyde (277.5 mg, 1.5 mmol). Isolated yield = 73%. ¹H NMR (400 MHz, CDCl₃) δ = 7.59 – 7.57 (m, 1H), 7.28 – 7.22 (m, 5H), 7.08 – 7.03 (m, 3H), 4.89 (s, 2H), 2.43 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.0, 171.5, 137.9, 136.9, 132.9, 131.3, 128.5, 128.5(1), 127.5, 127.4, 127.3, 118.7, 48.3, 26.5 ppm. HRMS (APCI) calcd for C₁₆H₁₄ BrNO₂ [M]⁺: 331.0209; found: 331.0208.



N-Acetyl-N-benzyl-4-chlorobenzamide (3af). Compound 3af was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-chlorobenzaldehyde (210.8 mg, 1.5 mmol). Isolated yield = 61%. ¹H NMR (400 MHz, CDCl₃) δ = 7.49 (d, *J* = 8.5 Hz, 2H), 7.39 (d, *J* = 8.5 Hz, 2H), 7.33 – 7.14 (m, 5H), 4.98 (s, 2H), 2.19 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.2,

173.0, 138.7, 137.0, 134.0, 129.7, 129.0, 128.6, 127.5, 127.5, 49.2, 26.2 ppm. HRMS (APCI) calcd for C₁₆H₁₄ ClNO₂ [M]⁺: 287.0717; found: 287.0720.



N-Acetyl-N-benzyl-2-chlorobenzamide (3ag). Compound 3ag was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 2-chlorobenzaldehyde (210.8 mg, 1.5 mmol). Isolated yield = 43%. ¹H NMR (400 MHz, CDCl₃) δ = 7.41 –7.31 (m, 2H), 7.27 – 7.21 (m, 4H), 7.11 – 7.07 (m, 3H), 4.90 (s, 2H), 2.41 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.0, 170.8, 136.9, 135.9, 131.3, 130.1, 129.8, 128.5, 127.4, 127.2, 127.0, 48.3, 26.4 ppm. HRMS (APCI) calcd for C₁₆H₁₄CINO₂ [M]⁺: 287.0715; found: 287.0713.



N-Acetyl-N-benzyl-4-iodobenzamide (3ah). Compound 3ah was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-iodobenzaldehyde (348.0 mg, 1.5 mmol). Isolated yield = 50%. ¹H NMR (400 MHz, CDCl₃) δ = 7.77 (d, *J* = 8.5 Hz, 2H), 7.33 – 7.15 (m, 7H), 4.97 (s, 2H), 2.19 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.5, 173.0, 138.0, 136.9, 135.0, 129.6, 128.6, 127.5, 99.6, 49.2, 26.3. ppm. HRMS (APCI) calcd for C₁₆H₁₄INO₂ [M]⁺: 379.0070; found: 379.0069.



N-Acetyl-N-benzyl-4-fluorobenzamide (3ai). Compound 3ai was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-fluorobenzaldehyde (186.2 mg, 1.5 mmol). Isolated yield = 67%. ¹H NMR (400 MHz, CDCl₃) δ = 7.60 – 7.56 (m, 2H), 7.30 – 7.20 (m,

5H), 7.10 (dd, J = 11.9, 5.1 Hz, 2H), 4.99 (s, 2H), 2.18 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 173.2$, 173.0, 166.3, 163.8, 137.0, 131.7(8), 131.7(5), 131.0, 130.9, 128.6, 127.6, 127.5, 116.1, 115.9, 49.3, 26.2 ppm. HRMS (APCI) calcd for C₁₆H₁₄FNO₂ [M]⁺: 271.1014; found: 271.1013.



N-Acetyl-N-benzyl-2-fluorobenzamide (3aj). Compound 3aj was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 2-fluorobenzaldehyde (186.2 mg, 1.5 mmol). Isolated yield = 46%. ¹H NMR (400 MHz, CDCl₃) δ = 7.47 – 7.45 (m, 1H), 7.39 – 7.35 (m, 1H), 7.29 – 7.09 (m, 7H), 4.98 (s, 2H), 2.34 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.1, 169.2, 159.7, 157.2, 133.0, 129.7, 129.6(9), 128.5, 127.4, 127.1, 124.6(3), 124.6(0), 116.0, 115.8, 48.6, 25.8 ppm. HRMS (APCI) calcd for C₁₆H₁₄FNO₂ [M]⁺: 271.1010; found: 271.1009.



N-Acetyl-N-benzyl-4-(trifluoromethyl)benzamide (3ak). Compound 3ak was prepared following the procedure starting from *N*-benzylacetamide (74.6)0.5 general mg, mmol) and 4-(trifluoromethyl)benzaldehyde (261.2 mg, 1.5 mmol). Isolated yield = 52%. ¹H NMR (400 MHz, CDCl₃) $\delta = 7.61-7.52$ (m, 4H), 7.22 - 7.09 (m, 5H), 4.91 (s, 2H), 2.17 (s, 3H) ppm; {}^{13}C NMR (100 MHz, CDCl₃) δ = 173.0, 172.8, 139.0, 136.7, 128.6, 128.2, 127.5, 127.2, 125.6, 49.0, 26.2. ppm. HRMS (APCI) calcd for C₁₇H₁₄F₃NO₂ [M]⁺: 321.0982; found: 321.0982.



N-Acetyl-N-benzyl-4-methoxybenzamide (3al). Compound 3al was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and 4-methoxybenzaldehyde (204.2 mg,

1.5 mmol). Isolated yield = 26%. ¹H NMR (400 MHz, CDCl₃) δ = 7.59 – 7.57 (m, 2H), 7.28 – 7.25 (m, 5H), 6.91 (d, *J* = 8.8 Hz, 2H), 5.00 (s, 2H), 3.86 (s, 3H), 2.11 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.8, 173.0, 163.3, 137.4, 131.1, 128.5, 127.9, 127.7, 127.4, 114.1, 55.5, 49.4, 26.1 ppm. HRMS (APCI) calcd for C₁₇H₁₇NO₃ [M]⁺: 283.1207; found: 283.1208.



N-Acetyl-N-benzylhexanamide (3am). Compound 3am was prepared following the general procedure starting from *N*-benzylacetamide (74.6 mg, 0.5 mmol) and hexanaldehyde (150.2 mg, 1.5 mmol). Isolated yield = 47%. ¹H NMR (400 MHz, CDCl₃) δ = 7.37 – 7.28 (m, 3H), 7.16 (d, *J* = 4.0 Hz, 2H), 4.99 (s, 2H), 2.69 (t, *J* = 7.4 Hz, 2H), 2.46 (s, 3H), 1.67 – 1.63 (m, 3H), 1.31 – 1.28 (m, 5H), 0.89 (t, *J* = 8.0 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 176.5, 173.6, 137.1, 128.8, 127.4, 126.1, 47.2, 37.8, 31.2, 26.8, 24.5, 22.4, 13.9 ppm. HRMS (APCI) calcd for C₁₅H₂₁NO₂ [M]⁺: 176.0708; found: 176.0712.



N-Acetyl-N-phenylbenzamide (3ba). Compound 3ba was prepared following the general procedure starting from *N*-phenylacetamide (67.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 75%. ¹H NMR (400 MHz, CDCl₃) δ = 7.64 (d, *J* = 8.0 Hz, 2H), 7.43 – 7.20 (m, 6H), 7.18 (d, *J* = 8.0 Hz, 2H) 2.46 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.5, 172.8, 139.1, 134.8, 132.1, 129.4, 129.2, 128.6, 128.3, 128.1, 25.7 ppm. HRMS (ESI) calcd for C₁₅H₁₃NO₂ [M+H]⁺: 240.1025; found: 240.1018.



N-Acetyl-N-(o-tolyl)benzamide (3ca). Compound 3ca was prepared following the general procedure

starting from *N*-(o-tolyl)acetamide (74.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 87%. ¹H NMR (400 MHz, CDCl₃) δ = 7.64 (d, *J* = 8.0 Hz, 2H), 7.41 – 7.11 (m, 7H), 2.36 (s, 3H), 2.30 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.4, 172.5, 138.1, 135.7, 135.0, 131.7, 131.2, 129.1, 128.7, 128.4, 128.0, 127.0, 25.4, 17.9 ppm. HRMS (APCI) calcd for C₁₆H₁₅NO₂ [M]⁺: 253.1106; found: 253.1108.



N-Acetyl-N-(p-tolyl)benzamide (3da). Compound 3da was prepared following the general procedure starting from *N*-(p-tolyl)acetamide (74.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 77%. ¹H NMR (400 MHz, CDCl₃) δ = 7.66 (d, *J* = 8.0 Hz , 2H), 7.41 – 7.11 (m, 7H), 2.36 (s, 3H), 2.30 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.7, 173.0, 138.1, 136.5, 135.0, 132.0, 130.1, 129.2, 128.2(7), 128.2(6), 25.6, 21.1 ppm. HRMS (APCI) calcd for C₁₆H₁₅NO₂ [M]⁺: 253.1105; found: 253.1108.



N-Acetyl-N-(4-methoxyphenyl)benzamide (3ea). Compound 3ea was prepared following the general procedure starting from *N*-(4-methoxyphenyl)acetamide (82.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 68%. ¹H NMR (400 MHz, CDCl₃) δ = 7.60 – 7.59 (m, 2H), 7.38 – 7.28 (m, 3H), 7.09 – 7.05 (m, 2H), 6.84 – 6.82 (m, 2H), 3.73 (s, 3H), 2.39 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.6, 172.8, 158.9, 134.8, 131.8, 131.5, 129.4, 128.9, 128.1, 114.5, 55.2, 25.4 ppm. HRMS (APCI) calcd for C₁₆H₁₅NO₃[M]⁺: 269.1051; found: 269.1052.



N-Acetyl-N-mesitylbenzamide (3fa). Compound 3fa was prepared following the general procedure starting from *N*-mesitylacetamide (88.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 99%. ¹H NMR (400 MHz, CDCl₃) δ = 7.65 (d, *J* = 8.0 Hz, 2H), 7.48 – 7.37 (m, 3H), 6.96 (s, 2H), 2.31 – 2.25 (m, 12H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 173.7, 172.1, 138.8, 135.7, 135.6, 134.9, 131.7, 129.8, 128.3, 128.1, 25.3, 21.1, 18.3 ppm. HRMS (APCI) calcd for C₁₈H₁₉NO₂ [M]⁺: 281.1412; found: 281.1416.



N-Acetyl-N-methylbenzamide (3ga). Compound 3ga was prepared following the general procedure starting from *N*-methylacetamide (36.5 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 71%. ¹H NMR (400 MHz, CDCl₃) δ = 7.64 – 7.47 (m, 5H), 3.22 (s, 3H), 2.34 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 174.2, 173.6, 135.2, 132.4, 128.8, 128.4, 34.4, 25.9 ppm. HRMS (APCI) calcd for C₁₀H₁₁NO₂ [M]⁺: 177.0788; found: 177.0790.



N-Acetyl-N-phenethylbenzamide (3ha). Compound 3ha was prepared following the general procedure starting from *N*-phenethylacetamide (81.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 78%. ¹H NMR (400 MHz, CDCl₃) δ = 7.51 – 7.37 (m, 5H), 7.25 – 7.18 (m, 3H), 7.09 (d, J = 8.0 Hz, 2H), 4.02 – 4.00 (m, 2H), 2.93 – 2.88 (m, 2H), 2.14 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃)

 $\delta = 174.1, 173.1, 138.0, 135.4, 132.0, 128.9, 128.5, 128.3, 128.0, 126.3, 47.7, 34.9, 26.1 ppm. HRMS (APCI) calcd for C₁₇H₁₇NO₂[M]⁺: 267.1264; found: 267.1264.$



N-Acetyl-N-butylbenzamide (3ia). Compound 3ia was prepared following the general procedure starting from *N*-butylacetamide (65.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 81%. ¹H NMR (400 MHz, CDCl₃) δ = 7.62 – 7.53 (m, 3H), 7.48 – 7.44 (m, 2H), 3.77 – 3.74 (m, 2H), 2.15 (s, 3H), 1.58 – 1.54 (m, 2H), 1.27 – 1.25 (m, 2H), 0.85 (t, *J* = 7.3 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 174.6, 173.2, 135.8, 132.4, 128.8, 128.4, 46.2, 31.1, 26.2, 20.1, 13.6 ppm. HRMS (APCI) calcd for C₁₃H₁₇NO₂ [M]⁺: 219.1263; found: 219.1264.



1-Benzoylazepan-2-one (3ja). Compound **3ja** was prepared following the general procedure starting from azepan-2-one (56.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 67%. ¹H NMR (400 MHz, CDCl₃) δ = 7.56 – 7.53 (m, 2H), 7.46 – 7.37 (m, 3H), 4.00 – 3.97 (m, 2H), 2.71 – 2.68 (m, 2H), 1.85 – 1.83 (m, 6H). ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 177.5, 174.1, 136.5, 131.3, 128.1, 127.6, 45.1, 38.8, 29.5, 29.1, 23.7 ppm. HRMS (APCI) calcd for C₁₃H₁₅NO₂ [M]⁺: 217.1098; found: 217.1103.



N-Phenyl-N-propionylbenzamide (3ka). Compound 3ka was prepared following the general procedure starting from *N*-phenylpropionamide (74.6 mg, 0.5 mmol) and benzaldehyde (159.2 mg, 1.5 mmol). Isolated yield = 47%. ¹H NMR (400 MHz, CDCl₃) δ = 7.65 – 7.63 (m, 2H), 7.44 – 7.31 (m, 6H), 7.20-7.18 (m, 2H), 2.71 (q, *J* = 7.4 Hz, 2H), 1.23 (t, *J* = 7.4 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 177.4, 173.0, 139.1, 135.1, 131.9, 129.4, 129.0, 128.7, 128.3, 128.1, 31.0, 9.5 ppm. HRMS (APCI) calcd for C₁₆H₁₅NO₂ [M]⁺: 253.1101; found: 253.1103.



2,2,6,6-Tetramethylpiperidin-1-yl benzoate (4)¹. Isolated yield = 78%. ¹H NMR (400 MHz, CDCl₃) δ = 8.10 – 8.08 (m, 2H), 7.59 – 7.57 (m, 1H), 7.50 – 7.46 (m, 2H), 1.97 – 1.46 (m, 6H), 1.29 (s, 6H), 1.14 (s, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 166.3, 132.8, 129.6, 129.5, 128.4, 60.3, 39.0, 31.9, 20.8, 16.9 ppm.















3af





— 4.90













--2.175





3aj



3ak



3al





3ba



3ca



3da



3ea



3fa





3ha



3ia











3ja





3la









8.104 8.086 8.083 7.571 7.571 7.496 7.477 7.458 1 W. Liu, Y. Li, K. Liu, Z. Li, J. Am. Chem. Soc. **2011**, *5*, 10756-10759.